Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bupropion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 5/20 | 1.00 |
| ▸ | CHRNG | P07510 | 5/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 5/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 5/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 5/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 5/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 5/20 | 1.00 |
| ▸ | CHRND | Q07001 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | ITGA5 | P08648 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bupropion SCHEMBL38777 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL30679332 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29354885 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL60314 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29424575 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL12499296 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL1237221 | 0.98 | SLC6A2 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL31748783 | 0.98 | SLC6A2 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL636116 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL41602 | 0.98 | SLC6A2 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3281628-B1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | NALPROPION PHARMACEUTICALS INC (US) | 2019-09-11 | — | — | EP | claimed |
| US-20110060037-A1 | USE OF NPY Y5 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF PSYCHO-STIMULANT AND OPIOID ABUSE | UNIVERSITY OF COPENHAGEN (DK) | 2011-03-10 | — | — | US | claimed |
| EP-2280703-A1 | USE OF NPY Y5 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF PSYCHOSTIMULANT AND OPIOID ABUSE | Københavns Universitet (University Of Copenhagen) (DK) | 2011-02-09 | — | — | EP | claimed |
| WO-2009112033-A1 | USE OF NPY Y5 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF PSYCHOSTIMULANT AND OPIOID ABUSE | KØBENHAVNS UNIVERSITET (UNIVERSITY OF COPENHAGEN) (DK) | 2009-09-17 | — | — | WO | claimed |
| US-20230270744-A1 | Methods of Administering Elagolix | ABBVIE INC. | 2023-08-31 | — | — | US | disclosed |
| CN-113116849-A | Preparation composition containing bupropion | 石家庄以岭药业股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-103826622-B | N-substituted phenylalamides or phenylalamides for the prophylaxis or treatment of affective disorders | 诺瓦麦有限公司 | 2016-06-08 | — | — | CN | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20110060037-A1 | USE OF NPY Y5 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF PSYCHO-STIMULANT AND OPIOID ABUSE | UNIVERSITY OF COPENHAGEN (DK) | 2011-03-10 | — | — | US | disclosed |
| EP-2280703-A1 | USE OF NPY Y5 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF PSYCHOSTIMULANT AND OPIOID ABUSE | Københavns Universitet (University Of Copenhagen) (DK) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009112033-A1 | USE OF NPY Y5 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF PSYCHOSTIMULANT AND OPIOID ABUSE | KØBENHAVNS UNIVERSITET (UNIVERSITY OF COPENHAGEN) (DK) | 2009-09-17 | — | — | WO | disclosed |
| EP-1682152-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | CNS RESPONSE (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1691811-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | Sepracor, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1682152-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | CNS Response (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005044190-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | CNS RESPONSE (US) | 2005-05-19 | — | — | WO | disclosed |
| US-6110973-A | ADMINISTERING TO HUMAN FOR WEIGHT REDUCTION OR WEIGHT CONTROL THERAPEUTICALLY EFFECTIVE AMOUNT OF (-)-BUPROPION OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, SUBSTANTIALLY FREE OF ITS (+)-STEREOISOMER | SEPRACOR (US) | 2000-08-29 | — | — | US | disclosed |
| US-6060642-A | TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270744-A1 | Methods of Administering Elagolix | CYP2D6, CYP2B6, CYP19A1 | SLC6A3 945/4885SLC6A2 984/4885CHRNA1 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.